Larger Vascular Access Catheters Expand Treatable Patient Population


August 11, 2010

New sizes of the SoloPath TransFemoral Endovascular Access Catheter provide the potential to treat a larger patient population with percutaneous stent grafts and heart valves.

The device allows access to the larger vascular anatomy at a relatively small catheter size and is then expanded to provide a conduit for the delivery of larger diameter devices.

The SoloPath Controlled Deployment Technology (CDT) is a different approach to procedures requiring minimally invasive access to remote sites within the body. The SoloPath enters the body at approximately one-half the diameter of conventional access sheaths, is very flexible and provides superior navigation through the vascular anatomy. Once in position, the device is deployed utilizing radial expansion to expand the sheath and remodel the tissue/vasculature in order to provide unrestricted access for the delivery of therapeutic devices.

The SoloPath allows minimally invasive access in a manner that is potentially less traumatic to the arterial vasculature compared to devices currently in use. By eliminating a number of surgical maneuvers, use of the SoloPath may reduce procedural time, surgical expense and patient recovery time.

The new sizes were cleared by the FDA in August 2010.

For more information: